.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Semaglutide in India is becoming significantly more affordable as domestic pharmaceutical companies enter the market with cheaper alternatives. Consequently, experts believe this shift will fundamentally change how clinicians treat obesity and type 2 diabetes across the country. However, medical professionals warn that this medication is not a "magic fix" for weight loss. Therefore, patients must use it under strict medical supervision to avoid complications.
The entry of multiple Indian pharmaceutical companies has triggered a massive price reduction. Estimates suggest that prices for semaglutide shots will drop by 60 to 80 percent soon. Moreover, this increased affordability allows a broader demographic to access advanced GLP-1 receptor agonist therapy. Dr. V. Mohan notes that earlier versions were already cheaper in India than in the US. However, current competition will make these life-altering drugs even more accessible to the general population. Besides affordability, clinicians observe that patients are now more aware of these therapies. Furthermore, some centers report successful reversals of diabetes in obese patients using these medications.
Despite the benefits, doctors express significant concerns regarding cosmetic misuse. Specifically, many individuals view the drug as a slimming agent rather than a chronic disease medication. This trend is often fueled by celebrity transformations seen on social media platforms. Additionally, the risk of over-medicalization remains a serious threat to public health. Dr. Satish Koul highlights that off-label use was already prevalent even before patents expired. Consequently, the CDSCO emphasizes that only qualified doctors should prescribe these drugs. Furthermore, unauthorized access through gyms or online platforms constitutes dangerous misuse. Therefore, tighter regulations are necessary to ensure patient safety and drug efficacy.
Common side effects of semaglutide include gastrointestinal issues like nausea, vomiting, and diarrhea. Moreover, rare but serious risks include pancreatitis and stomach paralysis. Patients must also understand that weight regain is almost certain if they discontinue the medication abruptly. Therefore, long-term adherence is essential for maintaining therapeutic results. Additionally, reliance on medication alone is insufficient for managing chronic obesity. Clinicians stress that diet and exercise remain the cornerstones of effective treatment. Finally, healthcare providers must monitor patients closely to adjust dosages and manage adverse events.
Q1: Is semaglutide a permanent solution for weight loss?
No, experts warn that weight regain is almost 100% if the drug is stopped. It should be treated as a long-term therapy for chronic disease management rather than a temporary fix.
Q2: What are the primary side effects of semaglutide?
The most common side effects are gastrointestinal, including nausea, vomiting, and diarrhea. Nausea alone can affect up to 50% of patients during the initial stages of treatment.
Q3: Can I buy semaglutide without a prescription in India?
No, the CDSCO and DCGI mandate that only qualified doctors should prescribe this medication. Using it without professional supervision is considered misuse and can lead to serious health risks.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Indian pharma price drops for semaglutide make obesity and diabetes care more accessible, but doctors warn against cosmetic misuse and rebound weight gain....
4 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
